We’re thrilled to announce our latest endeavor: the research and development of a C1-expressed biosimilar certolizumab for the treatment of inflammatory diseases. This groundbreaking project, generously funded by the ERDF of the European Union and the Junta de Castilla y León through the ICE, underscores our commitment to pushing the boundaries of biopharmaceutical innovation.

With the ultimate goal of improving patient outcomes and advancing the field of biomedicine, this project represents a significant step forward in the fight against inflammatory diseases. We’re honored to be at the forefront of this vital research, driving progress and making a tangible difference in healthcare.

RESEARCH AND DEVELOPMENT OF THE C1-EXPRESSED BIOSIMILAR CERTOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY DISEASES

File No: 04/18/VA/0079

Deadline for implementation: From 05/12/2019 to 31/03/2021

Project funded by the ERDF of the European Union and the Junta de Castilla y León, through the ICE, with the aim of promoting research, technological development and innovation.

INVESTIGACIÓN Y DESARROLLO DEL BIOSIMILAR CERTOLIZUMAB EXPRESADO EN C1 PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS

Expediente nº: 04/18/VA/0079

Plazo de realización: Desde el 05/12/2019 al 31/03/2021

Proyecto financiado por el FEDER de la Unión Europea y la Junta de Castilla y León, a través del ICE, con el objetivo de potenciar la investigación, el desarrollo tecnológico y la innovación.

About 53Biologics:

53Biologics is a CDMO with specialized in biologics production, from pDNA to proteins. In order to serve as leaders in biologics development and manufacturing, our mission is to support you whenever you need us, starting in preclinical development up to commercialization. 

For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com